Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)

Inclusion Criteria: * Age between 18 et 70 years * Patient accepting to give a written informed consent * Recipients of a first renal allograft * Cadaver or living transplantation or living (non HLA identical) donor with compatible ABO blood type. * Absence of positive DSA using Luminex®, MFI\>1,000 * Negative cross-match in cytotoxicity * Patient without difficulty to understand and communicate with the investigator and his collaborators * Patient entitled to Health System benefits or other such benefits. Exclusion Criteria: * Multiple organ transplantation * Recipients of a dual kidney transplant * Previous renal allograft * History of any other transplantation * Receiving a graft from a non-heart-beating donor * Patient BMI \> 35 * Patients with evidence of severe liver disease, including abnormal liver profile (AST, ALT, or total bilirubin \> 3 times upper limit of normal) at screening. * Significant severe infection, active peptic ulcer and/or difficulty to absorb oral drugs (active upper gastro-intestinal tract malabsorption syndrome) * HIV-positive patients, or with an active B or C hepatitis * Patients with de novo malignancy prior to transplantation, other than efficiently treated basal or squamous cell carcinoma of the skin. * Leucocyte count lower than 2500/mm3 * Female patients who are pregnant, lactating or of child bearing potential and not practicing an approved method of birth control. * Known allergy or intolerance to basiliximab, tacrolimus, macrolide antibiotics, corticosteroids, or mycophenolate mofetil or any of the product excipients * Participation in a clinical trial or expanded access trial with an investigational drug within 4 weeks prior to enrollment or concomitantly with this study * Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study